Ketiapiini

Ketiapiini is a term that appears in some linguistic contexts as a transliteration of the antipsychotic quetiapine. In major Western drug databases, the substance is not widely listed under this spelling, and reliable sources may instead refer to quetiapine directly. As a result, information about "ketiapiini" typically overlaps with that of quetiapine, and any use of the name should be cross-checked with standard references.

Quetiapine is an atypical antipsychotic used to treat schizophrenia, bipolar disorder, and, in some regions, major depressive disorder as an adjunct or monotherapy. It acts mainly as an antagonist of dopamine D2 and serotonin 5-HT2A receptors, with additional activity at histamine H1 and adrenergic receptors, contributing to its sedative and metabolic profiles. It is available in immediate-release and extended-release formulations.

Common adverse effects include drowsiness, dry mouth, dizziness, and weight gain, with possible metabolic changes such as dyslipidemia and hyperglycemia. Extrapyramidal symptoms are less frequent than with first-generation antipsychotics. Cardiac effects, including QT prolongation, and orthostatic hypotension can occur. Use is cautioned in elderly patients with dementia-related psychosis due to increased mortality risk; monitoring of weight, glucose, and lipids is recommended.

Quetiapine was developed by AstraZeneca and is marketed under the brand Seroquel and Seroquel XR. The drug is widely available as a generic and is prescribed globally for its approved indications and off-label uses in psychiatry. If the term "ketiapiini" is encountered in sources, it is advisable to verify whether it refers to quetiapine in a given language or transcription.